GlassScriptPhysician profile
Lynne M Bird
NPI 1487725230
$17,549.93
in general payments reported to CMS, 2019-2025
11 companies · $5,860 in 2025
The $5,860 reported for 2025 was more than what 79% of Clinical Genetics (M.D.) providers received nationally (typical 2025 total: $255).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $79.01 · 2020: $1,126 · 2021: $4,274 · 2022: $4,325 · 2023: $1,488 · 2024: $398 · 2025: $5,860.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Travel and Lodging: $2,666 · Consulting Fee: $2,358 · Compensation For Services Other Than Consulting, Including Serving As Faculty Or As A Speaker At A Venue Other Than A Continuing Education Program: $2,000 · Food and Beverage: $684 · Education: $38.00.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Travel and Lodging | $2,666.33 |
| Consulting Fee | $2,358.00 |
| Compensation For Services Other Than Consulting, Including Serving As Faculty Or As A Speaker At A Venue Other Than A Continuing Education Program | $2,000.00 |
| Food and Beverage | $684.24 |
| Education | $38.00 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Acadia Pharmaceuticals INC | $4,063.24 | 2023-2025 | Acp-101, Nuplazid |
| Ptc Therapeutics, INC. | $3,956.25 | 2021-2022 | |
| F. Hoffmann-La Roche Ag | $2,447.50 | 2020-2021 | |
| Radius Health, INC. | $1,920.00 | 2021 | |
| Ionis Pharmaceuticals, INC. | $1,824.27 | 2025 | |
| Genentech, INC. | $1,427.06 | 2023 | |
| Soleno Therapeutics, INC. | $1,360.60 | 2022-2025 | Vykat Xr |
| Sage Therapeutics, LLC | $358.00 | 2024 | |
| Biomarin Pharmaceutical INC. | $114.00 | 2020-2023 | |
| Biogen, INC. | $79.01 | 2019 |
1 company reported research payments only; those appear in the research section below.
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Lynne Bird listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.